Latest California Healthline Stories
Inside the Tactical Tug of War Over the Controversial Alzheimer’s Drug
An epic battle is playing out behind the scenes over whether the government should pay for Aduhelm, an FDA-approved Alzheimer’s drug that scientists say has not been proven to work.
Don’t Nurse That Moscow Mule — It Could Be a Health Hazard
Researchers in Montana have found that unsafe levels of copper can leach into the cocktail in less than half an hour.
Cuidado con este cóctel, puede ser peligroso para la salud
El Moscow Mule se toma en una jarra de cobre, lo que lo vuelve fascinante, y tal vez peligroso.
KHN’s ‘What the Health?’: FDA Takes Center Stage
Congress is set to start its once-every-five-years review of the law that authorizes user fees to finance the hiring of personnel to speed the FDA review of drugs. The periodic renewals of “PDUFA” also give lawmakers a chance to make other changes to the agency at the hub of the pandemic. Meanwhile, the FDA could also find itself at the center of the abortion debate and a controversial new medication to treat Alzheimer’s disease. Anna Edney of Bloomberg News, Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico, and Sarah Karlin-Smith of the Pink Sheet join KHN’s Julie Rovner to discuss these issues and more.
KHN’s ‘What the Health?’: Paging the HHS Secretary
Health and Human Services Secretary Xavier Becerra is drawing criticism for his hands-off handling of the covid crisis even though the heads of the Centers for Disease Control and Prevention, National Institutes of Health, and FDA report to him. Meanwhile, the Department of Labor looks to enforce mental health “parity laws” that have failed to achieve their goals. Margot Sanger-Katz of The New York Times, Alice Miranda Ollstein of Politico, and Rachel Cohrs of Stat join KHN’s Julie Rovner to discuss these issues and more. Also this week, Rovner interviews KHN’s Noam N. Levey, who reported and wrote the latest KHN-NPR “Bill of the Month” episode about a large emergency room bill for a small amount of medical care.
KHN’s ‘What the Health?’: Dealing With Drug Prices
Medicare officials tentatively plan to restrict the use of a controversial Alzheimer’s drug to only those patients participating in clinical trials, while the Department of Health and Human Services looks into lowering the monthly Medicare Part B premium. Meanwhile, covid confusion still reigns, as the Biden administration moves, belatedly, to make more masks and tests available. Joanne Kenen of Politico and the Johns Hopkins Bloomberg School of Public Health, Sarah Karlin-Smith of the Pink Sheet and Rachel Cohrs of Stat join KHN’s Julie Rovner to discuss these issues and more.
‘An Arm and a Leg’: The Rapid-Test Edition: Who’s Making a Buck?
In this episode, host Dan Weissmann talks to reporters who investigated the shortage of tests and traced the U.S. rapid-testing problem back to government agencies.
Vaccine Rollout Was a Success, But Events Within and Beyond Biden’s Control Stymied Progress
There were variants, vaccine hesitancy and messaging mix-ups. And, despite campaign promises, Biden and his administration sometimes took actions or made statements without waiting for full scientific evidence to back them up.
KHN’s ‘What the Health?’: Oh, Oh, Omicron
Even before the omicron variant of covid starts to spread widely in the U.S., hospitals are filling up with post-holiday delta cases. Meanwhile, the Supreme Court signals — loudly — that 2022 will be the year it rolls back abortion rights in a big way. Margot Sanger-Katz of The New York Times, Alice Miranda Ollstein of Politico and Mary Ellen McIntire of CQ Roll Call join KHN’s Julie Rovner to discuss these issues and more.
With Overdose Deaths Surging, Advocates on the Ground Push for Over-the-Counter Naloxone
Harm-reduction groups say that requiring a doctor to sign off on their orders of the overdose reversal drug is one of the biggest barriers they face in obtaining the lifesaving medication.